Praxis Precision Medicines, Inc. (PRAX)
Largest Insider Buys in Sector
PRAX Stock Price History Chart
PRAX Stock Performance
About Praxis Precision Medicines, Inc.
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential …
Insider Activity of Praxis Precision Medicines, Inc.
Over the last 12 months, insiders at Praxis Precision Medicines, Inc. have bought $0 and sold $1.09M worth of Praxis Precision Medicines, Inc. stock.
On average, over the past 5 years, insiders at Praxis Precision Medicines, Inc. have bought $2.55M and sold $8.67M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 14,500 shares for transaction amount of $25,375 was made by DeSimone Jill (director) on 2023‑10‑05.
List of Insider Buy and Sell Transactions, Praxis Precision Medicines, Inc.
| 2024-11-14 | Sale | General Counsel and Secretary | 8,239.33 0.0451% | $80.20 | $660,827 | -10.53% | ||
| 2024-11-14 | Sale | Principal Accounting Officer | 5,188.34 0.029% | $81.78 | $424,318 | -12.26% | ||
| 2023-10-05 | director | 14,500 0.0118% | $1.75 | $25,375 | -23.23% | |||
| 2023-06-27 | Chief Executive Officer | 10,000 0.0186% | $1.06 | $10,587 | -23.23% | |||
| 2023-03-24 | director | 50,000 0.0964% | $0.84 | $41,815 | +32.19% | |||
| 2023-03-24 | Chief Financial Officer | 8,000 0.0161% | $0.87 | $6,998 | +32.19% | |||
| 2023-03-23 | Chief Executive Officer | 70,001.75 0.1332% | $0.86 | $60,366 | +26.46% | |||
| 2022-06-16 | Principal Accounting Officer | 3,000 0.0065% | $1.93 | $5,775 | +14.95% | |||
| 2022-06-13 | General Counsel and Secretary | 7,500 0.0147% | $1.63 | $12,225 | +22.53% | |||
| 2022-06-09 | Chief Financial Officer | 10,000 0.0221% | $1.76 | $17,650 | +27.43% | |||
| 2022-06-08 | Chief Executive Officer | 27,000 0.0609% | $1.85 | $49,888 | +23.89% | |||
| 2022-06-08 | 25,000 0.0551% | $1.81 | $45,188 | +23.89% | ||||
| 2021-10-06 | Sale | 10 percent owner | 400,000 0.8% | $17.50 | $7M | -45.09% | ||
| 2021-10-05 | Sale | 10 percent owner | 23,946 0.0534% | $19.15 | $458,566 | -43.95% | ||
| 2021-10-01 | Sale | 10 percent owner | 22,600 0.0498% | $19.13 | $432,338 | -43.44% | ||
| 2021-08-31 | Chief Financial Officer | 3,905 0.0086% | $19.48 | $76,069 | -35.35% | |||
| 2021-08-23 | Sale | 10 percent owner | 352,396 0.7552% | $19.00 | $6.7M | -33.99% | ||
| 2021-08-18 | Sale | 10 percent owner | 3,000 0.0067% | $15.88 | $47,640 | -17.40% | ||
| 2021-08-18 | Chief Executive Officer | 9,542 0.021% | $15.79 | $150,668 | -17.40% | |||
| 2021-08-12 | Sale | 10 percent owner | 10,060 0.0226% | $13.92 | $140,035 | -4.00% |
Institutional Investor Ownership
| Adage Capital Partners Gp L L C | $85M | 8.14 | 1.39M | +88.59% | +$39.93M | 0.16 | |
| Cormorant Asset Management Lp | $79.94M | 7.66 | 1.31M | +106.84% | +$41.29M | 3.73 | |
| Point72 Asset Management | $58.22M | 5.58 | 954,140 | +37.83% | +$15.98M | 0.09 | |
| RA Capital Management, L.P. | $50.55M | 4.84 | 828,380 | New | +$50.55M | 0.05 | |
| Perceptive Advisors | $50.13M | 4.8 | 821,589 | New | +$50.13M | 0.03 |